Plasma concentration monitoring of oral vancomycin.
出版信息
Aust Prescr. 2025 Aug;48(4):148. doi: 10.18773/austprescr.2025.035.
Abstract
摘要
相似文献
1
Plasma concentration monitoring of oral vancomycin.口服万古霉素的血药浓度监测
Aust Prescr. 2025 Aug;48(4):148. doi: 10.18773/austprescr.2025.035.
2
Clinical Efficacy and Safety of Vancomycin Based on Unbound Vancomycin Concentration Monitoring.
Ther Drug Monit. 2024 Dec 10;47(4):504-511. doi: 10.1097/FTD.0000000000001292.
3
Vancomycin Dosing Assessment in a Tunisian Pediatric Population.
Ther Drug Monit. 2025 Jul 9. doi: 10.1097/FTD.0000000000001358.
4
Safe and effective use of vancomycin.万古霉素的安全有效使用。
Aust Prescr. 2025 Apr;48(2):54-59. doi: 10.18773/austprescr.2025.013.
5
On-Cell Stability of Digoxin, Lithium, Phenytoin, Valproic Acid, and Vancomycin for Therapeutic Drug Monitoring.
J Appl Lab Med. 2025 Sep 3;10(5):1285-1291. doi: 10.1093/jalm/jfaf076.
6
Evaluation of the appropriateness of vancomycin therapeutic drug monitoring in the intensive care unit with a clinical pharmacy approach, a cross-sectional study.采用临床药学方法对重症监护病房万古霉素治疗药物监测的适宜性进行评估：一项横断面研究
Eur J Hosp Pharm. 2024 Dec 30. doi: 10.1136/ejhpharm-2023-004073.
7
Therapeutic drug monitoring of free vancomycin concentration in practice: A new analytical technique based on the HFCF-UF sample separation method.治疗药物监测游离万古霉素浓度的实践：一种基于 HFCF-UF 样品分离方法的新分析技术。
Biomed Chromatogr. 2023 Mar;37(3):e5559. doi: 10.1002/bmc.5559. Epub 2022 Dec 19.
8
Guidelines for therapeutic drug monitoring of vancomycin: a systematic review.万古霉素治疗药物监测指南：一项系统评价
PLoS One. 2014 Jun 16;9(6):e99044. doi: 10.1371/journal.pone.0099044. eCollection 2014.
9
Development and validation of a dried plasma spot LC-MS/MS method for therapeutic monitoring of vancomycin and comparison with enzyme-multiplied immunoassay.
Biomed Chromatogr. 2023 Apr;37(4):e5586. doi: 10.1002/bmc.5586. Epub 2023 Feb 8.
10
[Predictive performance of Smart Dose, PharmVan and JPKD on Vancomycin plasma concentration].[Smart Dose、PharmVan和JPKD对万古霉素血药浓度的预测性能]
Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2021 Mar;33(3):263-268. doi: 10.3760/cma.j.cn121430-20201016-00674.
本文引用的文献
1
Safe and effective use of vancomycin.万古霉素的安全有效使用。
Aust Prescr. 2025 Apr;48(2):54-59. doi: 10.18773/austprescr.2025.013.
2
Australasian Society of Infectious Diseases updated guidelines for the management of Clostridioides difficile infection in adults and children in Australia and New Zealand.澳大拉西亚传染病学会发布的澳大利亚和新西兰成人及儿童艰难梭菌感染管理更新指南。
Intern Med J. 2025 Mar;55(3):503-513. doi: 10.1111/imj.16638. Epub 2025 Mar 4.
3
Systemic Absorption of Oral and Rectal Vancomycin in a Critically Ill Patient: A Case Report.一名重症患者口服和直肠用万古霉素的全身吸收：病例报告
Cureus. 2024 Dec 19;16(12):e76008. doi: 10.7759/cureus.76008. eCollection 2024 Dec.
4
Serum vancomycin concentrations after oral and intracolonic vancomycin administration in a patient with colonic discontinuity and severe infection.一名患有结肠连续性中断和严重感染的患者口服及结肠内给予万古霉素后的血清万古霉素浓度。
Am J Health Syst Pharm. 2018 May 1;75(9):e189-e193. doi: 10.2146/ajhp170200.
5
An extremely high bioavailability of orally administered vancomycin in a patient with severe colitis and renal insufficiency.一名患有严重结肠炎和肾功能不全的患者口服万古霉素后具有极高的生物利用度。
J Infect Chemother. 2017 Dec;23(12):848-851. doi: 10.1016/j.jiac.2017.08.004. Epub 2017 Oct 12.
6
Risk factors for systemic vancomycin exposure following administration of oral vancomycin for the treatment of Clostridium difficile infection.口服万古霉素治疗艰难梭菌感染后全身暴露于万古霉素的危险因素。
Pharmacotherapy. 2015 Feb;35(2):119-26. doi: 10.1002/phar.1538.
Zotero 插件